Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas’ registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click ...

文章核心观点 零售投资者若在Zenas BioPharma 2024年9月首次公开募股中购买股票且有损失，可考虑在2025年6月16日前申请成为证券集体诉讼的首席原告 [1][6] 案件情况 - 诉讼已在美国马萨诸塞州区联邦地方法院提起，指控Zenas BioPharma在首次公开募股注册文件中虚报财务状况 [4] - Zenas BioPharma称有足够资金运营24个月，但几周后第三季度财报显示资金仅够维持12个月 [4] - 自首次公开募股以来，Zenas BioPharma股价下跌近49%，从每股17美元降至2025年4月15日的8.72美元 [4] 首席原告相关 - 首席原告在诉讼中起积极作用，与律师合作代表所有集体成员利益，法院通常任命经济利益最大且能代表集体的投资者 [5] - 申请成为首席原告并非分享最终赔偿的必要条件，但可在诉讼中发声并参与制定策略 [6] 律所情况 - Cohen Milstein是美国领先的原告方律师事务所，专注证券诉讼和投资者保护 [7] - 该律所帮助股东追回数十亿美元赔偿，近期在富国银行证券诉讼案中追回10亿美元 [7] - 该律所及其律师被行业出版物评为美国最佳证券诉讼律师之一 [7]

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Zenas and certain of its o ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the fi ...

NEW YORK, April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statemen ...

WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- Investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who bought shares in the company’s September 2024 IPO may be eligible to participate in and lead a class action lawsuit now pending in federal court. Cohen Milstein Sellers & Toll PLLC, a nationally recognized investor rights law firm, is actively investigating claims and encouraging shareholders with significant losses to reach out now. [Click here for information about joining the class action] If you’d like t ...

文章核心观点 - 针对购买Zenas BioPharma公司IPO相关证券的投资者发起集体诉讼，指控公司、高管、董事及承销商违反联邦证券法，因招股说明书存在重大不实陈述或遗漏，致公司股价大幅下跌 [1][5][6] 案件基本信息 - 集体诉讼代表购买或获取Zenas BioPharma公司IPO相关证券的人士发起，指控公司、部分高管和董事及IPO承销商违反联邦证券法 [1] - Zenas投资者需在2025年6月16日前申请成为集体诉讼的首席原告，可通过指定网址、电话或邮件联系获取信息 [2][3] 公司情况 - Zenas是临床阶段的全球制药公司，开发和商业化针对自身免疫性疾病患者的免疫疗法 [4] 案件指控内容 - 诉讼称IPO招股说明书存在重大事实不实陈述或遗漏，包括夸大公司用现有现金和IPO预期净收益维持运营的时间，致被告公开声明虚假误导且准备疏忽 [5] - 2024年11月12日真相披露，公司季度报告显示现有资金仅够维持12个月运营，需额外融资，公司股价从IPO的每股17美元大幅下跌 [5] - 诉讼提交当日，Zenas股价收于8.33美元，较IPO价格下跌49% [6] 律所信息 - DiCello Levitt致力于通过多种诉讼为客户争取正义，律师能力受尊重，获多项行业认可 [7][8][9] 媒体联系方式 - 联系人Amy Coker，地址为4747 Executive Drive, Suite 240, San Diego, CA 92121，电话619 - 963 - 2426，邮箱investors@dicellolevitt.com [10]

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration sta ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Capti ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=144444&from=3  CLASS PERIOD: T ...